Concepedia

Publication | Open Access

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors

DOIFull Paper Access

22

Citations

18

References

2022

Year

Takashi Kawahara, Koji Kawai, Takahiro Kojima, Yoshiyuki Nagumo, Shotarou Sakka, Shuya Kandori, Hiromitsu Negoro, Bryan J. Mathis, Kazushi Maruo, Kōji Miura,
International Journal of Urology

Abstract

Tumor mutation burden is a potential biomarker for future testing of germ cell tumor response.

References

YearCitations

Page 1